Today's Date: September 25, 2023
2023 Gangnam Festival to be Held in Gangnam, the Heart of K-pop   •   Statement by the Prime Minister on Yom Kippur   •   France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival   •   Joint Statement on the Importance of Comprehensive, Multidisciplinary and Collaborative Care for Patients with Peripheral Artery   •   No more oil, gas and coal. Two nation-states join growing bloc of countries calling for a Fossil Fuel Non-Proliferation Treaty   •   Student Entrepreneurs from Yale University Win Prestigious $1 Million 2023 Hult Prize   •   Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo   •   Statement by Minister Khera on Yom Kippur   •   Reactive Technologies’ Grid Inertia Measurement Tech to Enable Offshore Wind Rollout in Taiwan   •   Wondershare FamiSafe 7.0 safeguarding Children with AI   •   Guidewire Optimistic About New Direction of California Insurance   •   2023 GLOBAL CITIZEN FESTIVAL SEES $240 MILLION COMMITMENT FROM FRANCE AND NORWAY TO COMBAT THE GLOBAL FOOD CRISIS   •   PRAIRIE VIEW A&M UNIVERSITY ANNOUNCES 2023-2024 WRITER-IN-RESIDENCE ATTICA LOCKE   •   65+ Populations in Upstate NY's 4 Largest Regions Surging, Getting Poorer; AARP NY to Meet with Local Leaders   •   Shift4 Partners with Give Lively to Offer Powerful Fundraising Solution to Nonprofits   •   THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON   •   Sixth Annual War Heroes on Water Charity Sportfishing Tournament Kicks Off, Bringing Hope and Healing to Combat-Wounded Veterans   •   Intel Editorial: Intel Addresses Semiconductor Workforce Shortage   • collaborates with   •   A Meyers Manx Collaboration with Artist Sage Vaughn Contributes $200,000 to Arts Education Fundraiser
Bookmark and Share

Stallergenes Greer Showcases Clinical Relevance and Persisting Benefits of Its Allergen Immunotherapy Treatments at 2023 EAACI C

BAAR, Switzerland , June 09 /Businesswire/ - Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), will be hosting a company-sponsored symposium entitled “Patient’s perspective: A must have for the future of Allergen Immunotherapy” at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress taking place June 9-11 in Hamburg (Germany). During the symposium, four of the world’s leading experts in respiratory allergy will showcase advancements regarding the clinical relevance of its AIT treatments, which contribute to furthering precision medicine and enhance patient benefits.

Stallergenes Greer is committed to therapeutic progress to meet the needs of patients and the medical community. Our personalised allergen immunotherapy solutions are supported by a wealth of data documenting their effectiveness, and by integrating the patient’s voice into each stage of the lifecycle of our treatments, we further ensure that our treatments meet their expectations. From the first months of treatment, and with an effect that consolidates over time, allergen immunotherapy may provide concrete, substantial and persisting patient benefits,” stated Amer Jaber, Executive VP Operations Europe and International and President of Stallergenes SAS.

During the congress, Stallergenes Greer will also present 13 abstracts on precision medicine in AIT and patient benefits and announce new data from clinical trials (EfficAPSI, Practis, and long-term data generated in Japan).


SYMPOSIUM (June 9: 12:00 – 13:00)

“Patient’s perspective: A must have for the future of allergen immunotherapy.”

Chair: Prof. Giorgio Walter Canonica, Italy.

- “What can a patient expect from AIT in the short term? Lessons learned from Randomized Controlled Clinical trials (RCT)”, speaker Prof. Randolf Brehler, Germany.

- “Which persisting benefits may patients anticipate with AIT over time? Lessons learned from Real World Evidence, speaker Prof. Pascal Demoly, France.

- “What do patients have to say about their experience with AIT? Lessons learned from Patient Reported Outcomes”, speaker Prof. Carmen Vidal, Spain.


EfficAPSI is the largest retrospective real-world, longitudinal cohort study regarding sublingual liquid allergen immunotherapy treatment. Its objective is to evaluate the real-life impact of sublingual liquid allergen immunotherapy on the onset and worsening of asthma in patients with allergic rhinitis. This study included more than 100,000 patients in France with allergic rhinitis with or without asthma treated with sublingual liquid AIT and symptomatic drugs and more than 330,000 patients with allergic rhinitis with or without asthma treated with symptomatic drugs only.

PRACTIS is a French multicentre real-world observational prospective one-year study. It evaluates over 1,000 allergic children, adolescents and adults treated in current practice with sublingual immunotherapy (tablets and sublingual solutions) to analyse how SLIT treatment meets patient expectations through the patient benefit index.


The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 13,000 members from 125 countries and over 75 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy.


Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information:

STORY TAGS: Conference, Biotechnology, General Health, Other Health, Health, Cardiology, Switzerland, Europe,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News